Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

Eli Lilly · Phase 1/2 · Active, not recruiting · Enrollment 190

NCT06700538

ArmPopulationDoseWeeksEstimandWeight change
Part 1: ARO-INHBEObesity or overweightn/rn/rn/rn/r
Part 1: PlaceboObesity or overweightn/rn/rn/rn/r
Part 2: ARO-INHBE + TirzepatideObesity or overweightn/rn/rn/rn/r
Part 2: Placebo + TirzepatideObesity or overweightn/rn/rn/rn/r
Part 3: ARO-INHBEObesity or overweightn/rn/rn/rn/r
Part 3: PlaceboObesity or overweightn/rn/rn/rn/r
Part 3: ARO-INHBE + TirzepatideObesity or overweightn/rn/rn/rn/r
Part 3: Placebo + TirzepatideObesity or overweightn/rn/rn/rn/r